WRBY Form 144: Neil H. Blumenthal Plans 50,000-Share Sale via Morgan Stanley
Rhea-AI Filing Summary
Warby Parker Inc. Form 144: This filing discloses a proposed sale of 50,000 common shares on or about 08/13/2025 through Morgan Stanley Smith Barney LLC on the NYSE with an aggregate market value of $1,220,500.00. The shares were acquired on 12/04/2019 through previously exercised stock options and were paid in cash. The company’s outstanding share count is reported as 105,187,778, so the proposed sale represents roughly 0.05% of outstanding common shares.
The filing also lists two recent Rule 10b5-1 sales by the same account in July 2025: 49,600 shares on 07/21/2025 for $1,200,786.24 and 400 shares on 07/18/2025 for $9,604.00. The filer affirms the standard representation about lack of undisclosed material adverse information.
Positive
- Transaction disclosed under Rule 144/10b5-1 providing transparency around insider sales
- Details provided on acquisition date and method (12/04/2019 via exercised stock options), enabling clear provenance of shares
Negative
- None.
Insights
TL;DR: Routine, pre-arranged insider sale disclosed under Rule 144/10b5-1 with negligible size relative to outstanding shares.
The filing shows a proposed sale of 50,000 common shares by the account linked to Neil Harris Blumenthal, acquired via exercised options in 2019. The sale is to be executed through Morgan Stanley on the NYSE and is reported alongside July 2025 10b5-1 sales totaling 50,000 shares. At ~0.05% of the company's 105,187,778 outstanding shares, this transaction is immaterial to capital structure. Disclosure complies with Form 144 requirements and includes the standard issuer-information representation.
TL;DR: Insider sales documented and transparent; size and recent sale history suggest routine liquidity, not a material market event.
The aggregate market value for the proposed 50,000-share sale is listed as $1,220,500.00. The filer previously sold 49,600 and 400 shares in July 2025 for $1,200,786.24 and $9,604.00 respectively, indicating execution under an established 10b5-1 plan. Given the acquisition date of 12/04/2019 and payment in cash, these are post-vesting option dispositions. From a market-impact perspective, the volumes are small relative to outstanding shares and unlikely to affect valuation materially.